BamSEC and AlphaSense Join Forces
Learn More

Dyne Therapeutics Inc. – Material Contracts

NASDAQ: DYN    
Share price (6/3/26): $17.99    
Market cap (6/3/26): $2.974 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.25
from 10-K 184 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions
12/34/56
EX-10.17
from 10-K 13 pages 2024 Inducement Stock Incentive Plan of Dyne Therapeutics, Inc
12/34/56
EX-10.1
from 10-Q 75 pages Agreement
12/34/56
EX-10.1
from 8-K 87 pages Agreement
12/34/56
EX-10.5
from 10-Q 10 pages Consulting Agreement
12/34/56
EX-10.4
from 10-Q 10 pages Via Electronic Mail March 27, 2025 Richard Scalzo [***] Dear Richard
12/34/56
EX-10.3
from 10-Q 4 pages Material contract
12/34/56
EX-10.1
from 8-K 17 pages Erick J. Lucera March 18, 2025 [***] Dear Erick: On Behalf of Dyne Therapeutics, Inc. (The “Company”), I Am Pleased to Offer You Employment in the Position of Chief Financial Officer. This Letter Summarizes the Initial Terms of Your Employment With the Company
12/34/56
EX-10.3
from 10-Q 9 pages Consulting Agreement
12/34/56
EX-10.2
from 10-Q 9 pages Consulting Agreement
12/34/56
EX-10.1
from 10-Q 18 pages Material contract
12/34/56
EX-10.6
from 10-Q 7 pages Dyne Therapeutics, Inc. Restricted Stock Unit Agreement Granted Under 2024 Inducement Stock Incentive Plan
12/34/56
EX-10.5
from 10-Q 5 pages Dyne Therapeutics, Inc. Nonstatutory Stock Option Agreement Granted Under 2024 Inducement Stock Incentive Plan
12/34/56
EX-10.5
from 8-K 10 pages 2024 Inducement Stock Incentive Plan of Dyne Therapeutics, Inc
12/34/56
EX-10.4
from 8-K 8 pages Consulting Agreement
12/34/56
EX-10.3
from 8-K 16 pages Via Electronic Mail March 25, 2024 Joshua Brumm [***] Dear Josh
12/34/56
EX-10.1
from 8-K 18 pages Execution Version John Cox March 21, 2024 [***] Dear John: On Behalf of Dyne Therapeutics, Inc. (The “Company”), I Am Pleased to Offer You Employment in the Position of President and Chief Executive Officer. This Letter Summarizes the Terms of Your Employment With the Company
12/34/56
EX-10.1
from 10-Q 21 pages Dyne Therapeutics, Inc. Amended and Restated Executive Severance and Change in Control Benefits Plan 1
12/34/56
EX-10.2
from 10-Q 15 pages Via Electronic Mail June 2, 2021 Romesh Subramanian 9 Alan Street Framingham, Ma 01701 Dear Romesh
12/34/56
EX-10.1
from 10-Q 64 pages 1560 Trapelo Road Lease Bp3-Bos1 1560 Trapelo Road LLC, a Delaware Limited Liability Company, as Landlord, and Dyne Therapeutics, Inc., a Delaware Corporation, as Tenant Summary of Basic Lease Information
12/34/56